Nkarta, Inc. (NKTX) stock
NKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.25+0.04 (+3.31%)
Close on Nov 17, 2026Market cap $89.53MP/E –Yield 0.00%
Nkarta r&d expenses
Research and development expenses are spending on new products and technology.
Nkarta's R&D Expenses for the twelve months ending Jun 30, 2026 was $99.51M, up 6.6% year over year. For fiscal 2025 it was $90.43M, down 6.5% from the year before. The highest annual figure on record is $96.77M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.43M | -6.5% |
| FY2024 | Dec 31, 2024 | $96.74M | -0.0% |
| FY2023 | Dec 31, 2023 | $96.77M | +6.5% |
| FY2022 | Dec 31, 2022 | $90.90M | +43.3% |
| FY2021 | Dec 31, 2021 | $63.41M | +75.1% |
| FY2020 | Dec 31, 2020 | $36.22M | +110.4% |
| FY2019 | Dec 31, 2019 | $17.22M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $29.05M | +39.8% |
| Q1 FY2026 | Mar 31, 2026 | $24.99M | +3.4% |
| Q4 FY2025 | Dec 31, 2025 | $25.28M | +9.3% |
| Q3 FY2025 | Sep 30, 2025 | $20.20M | -20.0% |
| Q2 FY2025 | Jun 30, 2025 | $20.78M | -10.2% |
| Q1 FY2025 | Mar 31, 2025 | $24.17M | -4.2% |
| Q4 FY2024 | Dec 31, 2024 | $23.13M | -0.8% |
| Q3 FY2024 | Sep 30, 2024 | $25.25M | +13.8% |
| Q2 FY2024 | Jun 30, 2024 | $23.13M | -7.9% |
| Q1 FY2024 | Mar 31, 2024 | $25.24M | -3.4% |
| Q4 FY2023 | Dec 31, 2023 | $23.32M | -13.1% |
| Q3 FY2023 | Sep 30, 2023 | $22.19M | -5.3% |
| Q2 FY2023 | Jun 30, 2023 | $25.12M | +19.4% |
| Q1 FY2023 | Mar 31, 2023 | $26.14M | +33.6% |
| Q4 FY2022 | Dec 31, 2022 | $26.84M | +55.2% |
| Q3 FY2022 | Sep 30, 2022 | $23.44M | +41.0% |
| Q2 FY2022 | Jun 30, 2022 | $21.05M | +31.9% |
| Q1 FY2022 | Mar 31, 2022 | $19.57M | +44.5% |
| Q4 FY2021 | Dec 31, 2021 | $17.30M | +53.5% |
| Q3 FY2021 | Sep 30, 2021 | $16.62M | +69.1% |
| Q2 FY2021 | Jun 30, 2021 | $15.96M | +103.0% |
| Q1 FY2021 | Mar 31, 2021 | $13.54M | +86.5% |
| Q4 FY2020 | Dec 31, 2020 | $11.27M | +68.7% |
| Q3 FY2020 | Sep 30, 2020 | $9.83M | +112.7% |
| Q2 FY2020 | Jun 30, 2020 | $7.86M | +117.1% |
| Q1 FY2020 | Mar 31, 2020 | $7.26M | – |
| Q4 FY2019 | Dec 31, 2019 | $6.68M | – |
| Q3 FY2019 | Sep 30, 2019 | $4.62M | – |
| Q2 FY2019 | Jun 30, 2019 | $3.62M | – |
See a number that looks wrong?